# A prospective multicenter study on prognostic factors and quality of care in Severe Acquired Brain Injury rehabilitation units: a project from the Tiresia network

## TL;DR

This study aims to identify factors affecting recovery and evaluate care quality for patients with severe brain injuries through a large-scale, multi-center research project.

## Contribution

The Tiresia project introduces a multicenter, prospective study to identify prognostic factors and quality indicators for severe acquired brain injury rehabilitation.

## Key findings

- The study involves 27 Italian intensive rehabilitation units collecting data on sABI patients.
- It emphasizes ethical standards and data quality to improve evidence-based care for sABI patients.

## Abstract

Severe Acquired Brain Injury (sABI) presents significant challenges in clinical management and rehabilitation due to its diverse and complex nature. The primary objective of the Tiresia project is to identify medium and medium-to-long-term prognostic factors for patients with sABI and to develop outcome indicators to evaluate the quality of care in rehabilitation units.

This paper outlines the protocol for a prospective observational multicenter study conducted within the Tiresia Network. The study relies on a comprehensive data collection with stringent quality control measures. Ethical considerations emphasize patient privacy protection and adherence to regulatory standards. All of the Italian intensive rehabilitation units dedicated to sABI patients were eligible to participate in the study. Twenty-seven of them joined the project and started the data collection.

The present study represents a comprehensive effort to address critical gaps in sABI research and practice through a multicenter, prospective study design. Through rigorous data collection, analysis, and ethical oversight, the Tiresia project endorses the commitment of the research community to advancing evidence-based care and optimizing patient outcomes in sABI rehabilitation.

The study was registered on ClinicalTrials.gov (ID: NCT04905264), on 24 May 2021.